Chemed stock holds near 500 dollars as analysts highlight 2026 earnings path

Published on 09/19/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chemed stock traded around 503 dollars on September 18, 2026, while analysts see full-year 2026 EPS near 23.55 and guidance at 25 to 25.75 dollars. The company’s valuation now hinges on delivering against this earnings trajectory.

CHE, US1638321034, Illustration mit AI erstellt.

Chemed Corporation stock (ISIN US1638321034) is trading just above 500 dollars, with the latest reference price of 503.12 dollars on the New York Stock Exchange as of September 18, 2026, keeping the shares close to their consensus analyst price target.

Earnings guidance drives Chemed stock narrative

According to MarketBeat, Chemed has issued guidance for fiscal year 2026, targeting earnings per share between 25.00 and 25.75 dollars, which sets a clear benchmark for investors evaluating the stock.

Research analysts cited by MarketBeat currently expect Chemed to deliver 23.55 dollars earnings per share in the current fiscal year 2026, implying a potential increase of around 1.45 to 2.20 dollars per share if the company reaches the midpoint or upper end of its 2026 guidance range.

Analyst views and valuation context

As reported by MarketBeat on September 19, 2026, one research analyst currently rates Chemed stock as Buy, while five assign Hold ratings, resulting in an average rating of Hold and a consensus price target of 530.75 dollars.

With the stock opened at 503.12 dollars on September 18, 2026, per data summarized by MarketBeat, the shares currently trade about 27.63 dollars, or roughly 5.5%, below the consensus target of 530.75 dollars, which frames an upside scenario if Chemed delivers on its earnings guidance.

Stock price level and investor perspective

Chemed stock most recently opened at 503.12 dollars on the New York Stock Exchange on September 18, 2026, in United States dollars, placing the shares in the upper price range for the company over the past year and leaving a modest gap to the consensus analyst price target.